ATLANTA, GA--(Marketwired - May 9, 2016) -  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, has provided its shareholders with an annual update letter. The letter is distributed in GeoVax's 2015 Annual Report to Shareholders mailed on May 2, and can be read in full by visiting the following link:

In the letter, GeoVax President and CEO, Robert McNally, Ph.D, and Chairman, David Dodd, update shareholders on the Company's continued efforts to increase shareholder value through its key initiatives, which include:

  • The development of a vaccine to prevent Zika virus infection under multiple collaborative arrangements;
  • New efforts to apply the Company's MVA-VLP technology to cancer immunotherapy;
  • Expansion of the Company's hemorrhagic fever vaccine program with the goal of a safe and effective single vaccine to prevent infection from two lethal strains of Ebola virus, plus Marburg and Lassa Fever viruses; and
  • Preventive HIV vaccine clinical trial initiatives and follow-on development activities with the National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN).

About GeoVax

GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. The Company's most advanced development programs are focused on vaccines against HIV and hemorrhagic fever viruses (Ebola, Marburg, Lassa). GeoVax also recently began programs to develop a vaccine against the Zika virus, and to evaluate the use of its MVA-VLP platform in cancer immunotherapy. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.

Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the NIH-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax's HIV vaccines, in various doses and combinations, have been tested in 500 humans with very encouraging results. Currently, GeoVax has the most advanced vaccine for the subtype of HIV prevalent in North America and Western Europe. The company awaits funding for a Phase 2b efficacy trial to prove the vaccine protects against HIV. For more information, visit

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

Contact Information:

GeoVax Labs, Inc.
Robert T. McNally, Ph.D.